Skip to main content
. Author manuscript; available in PMC: 2014 Nov 4.
Published in final edited form as: Vaccine. 2013 Sep 16;31(46):10.1016/j.vaccine.2013.09.010. doi: 10.1016/j.vaccine.2013.09.010

Table 1.

Neutralizing and binding activities of serum Abs from mice immunized with gp120 versus gp120/654

Mice immunized with HIV-1 isolate Tiera % Neutralizationb Ab binding to V3c Ab binding to gp120d Ab binding to native Envf
gp120JRFL SF162 1A 51.9 ± 4.4 +e +++ Yes
MN 1A 51.0 ±3.8 +++ + nt
HXB-2 1B ≤20 ++ nt
SS1196.1 1B ≤20 + ++ nt
6535 1B ≤20 ++ ++ nt
3988.25 1B ≤20 ++ nt
JRFL 2 ≤20 ++ +++ No
YU2 2 ≤20 ++ ++ nt
WITO 2 ≤20 ++ +++ nt
TRJO 3 ≤20 ++ nt

gp120JRFL/654 SF162 1A 88.0 ±4.6 +++ +++ Yes
MN 1A 78.0 ±2.8 +++ ++ nt
HXB-2 1B 28.3 ±3.2 + ++ nt
SS1196.1 1B 70.0 ±2.3 +++ ++ nt
6535 1B 42.0 ±4.0 +++ +++ nt
3988.25 1B 56.1 ±1.8 + ++ nt
JRFL 2 ≤20 +++ +++ No
YU2 2 ≤20 ++ ++ nt
WITO 2 ≤20 +++ ++ nt
TRJO 3 28.4 ±2.3 ++ ++ nt
a

As previously defined in (36).

b

Neutralization of pseudoviruses with different HIV envelopes by sera (1:50 dilution) collected at two weeks after the last immunization in the standard TZM/bl assay. Neutralization above 50% is shown in bold.

c

ELISA reactivity against V3 peptides of the corresponding viruses at 1:100 serum dilution.

d

ELISA reactivity against gp120 proteins from the corresponding viruses at 1:500 serum dilution.

e

Average OD405 values are summarized as follows: (−) 0.2–0.5; (+) 0.5–1.0; (++) 1.0–2.5; (+++) 2.5–3.5.

f

Binding to membrane-bound HIV envelopes on transfected 293T cells as measured by flow cytometry; nt: not tested